Cargando…

Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder

Background and Objectives: To determine changes in the blood pressure (BP) and pulse rate (PR) before and after the administration of mirabegron in real-world clinical practice for patients with overactive bladder (OAB). Materials and Methods: This study was conducted in patients newly diagnosed wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Hidenori, Matsuo, Tomohiro, Mitsunari, Kensuke, Ohba, Kojiro, Miyata, Yasuyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228850/ https://www.ncbi.nlm.nih.gov/pubmed/35744088 http://dx.doi.org/10.3390/medicina58060825

Ejemplares similares

Excessive accumulation of visceral fat is associated with lower urinary symptoms including overactive bladder in female patients
por: Otsubo, Asato, et al.
Publicado: (2020)

Presurgical bladder wall thickness is a useful marker to predict the postsurgical improvement of symptoms in patients with pelvic organ prolapse‐related overactive bladder
por: Otsubo, Asato, et al.
Publicado: (2021)

Efficacy of salt reduction for managing overactive bladder symptoms: a prospective study in patients with excessive daily salt intake
por: Matsuo, Tomohiro, et al.
Publicado: (2021)

Relationship between Urinary Calcium Excretion and Lower Urinary Tract Symptoms
por: Matsuo, Tomohiro, et al.
Publicado: (2022)

Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus‐1 associated myelopathy
por: Matsuo, Tomohiro, et al.
Publicado: (2018)

The Relationship between the Presence of an Earlobe Crease and Overactive Bladder: A Cross-Sectional Case-Controlled Study
por: Ueda, Yasufumi, et al.
Publicado: (2023)

A Review of Oxidative Stress and Urinary Dysfunction Caused by Bladder Outlet Obstruction and Treatments Using Antioxidants
por: Miyata, Yasuyoshi, et al.
Publicado: (2019)

High Expression of HuR in Cytoplasm, but Not Nuclei, Is Associated with Malignant Aggressiveness and Prognosis in Bladder Cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2013)

Efficacy of Tadalafil Therapy and Changes in Oxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder
por: Matsuo, Tomohiro, et al.
Publicado: (2019)

Left atrial metastasis of renal cell carcinoma: a case report and review of the literature
por: Ohba, Kojiro, et al.
Publicado: (2014)

Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

Pathological Significance of Macrophages in Erectile Dysfunction Including Peyronie’s Disease
por: Miyata, Yasuyoshi, et al.
Publicado: (2021)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men
por: Matsuo, Tomohiro, et al.
Publicado: (2016)

Met in Urological Cancers
por: Miyata, Yasuyoshi, et al.
Publicado: (2014)

Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2020)

Pathological roles of c-Met in bladder cancer: Association with cyclooxygenase-2, heme oxygenase-1, vascular endothelial growth factor-A and programmed death ligand 1
por: Mukae, Yuta, et al.
Publicado: (2020)

Oral administration of E-type prostanoid (EP) 1 receptor antagonist suppresses carcinogenesis and development of prostate cancer via upregulation of apoptosis in an animal model
por: Masato, Masahito, et al.
Publicado: (2021)

Patient utilization survey of mirabegron prescribed for overactive bladder
por: Rahkola-Soisalo, Päivi, et al.
Publicado: (2019)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
por: Sharaf, Ala’a, et al.
Publicado: (2017)

Pathological and Pharmacological Roles of Mitochondrial Reactive Oxygen Species in Malignant Neoplasms: Therapies Involving Chemical Compounds, Natural Products, and Photosensitizers
por: Miyata, Yasuyoshi, et al.
Publicado: (2020)

Mechanisms Underlying the Inhibition of Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and the Correlation between Macrophage Colony Stimulating Factor and Inflammatory Mediators
por: Yuno, Tsutomu, et al.
Publicado: (2020)

Molecular Mechanisms of the Anti-Cancer Effects of Isothiocyanates from Cruciferous Vegetables in Bladder Cancer
por: Mastuo, Tomhiro, et al.
Publicado: (2020)

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
por: Gubbiotti, Marilena, et al.
Publicado: (2019)

Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
por: Shaw, Christina, et al.
Publicado: (2023)

Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non‐muscle‐invasive bladder cancer: a randomised clinical trial
por: Miyata, Yasuyoshi, et al.
Publicado: (2021)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
por: Andersson, Karl-Erik
Publicado: (2013)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
por: Makhani, Asad, et al.
Publicado: (2020)

Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
por: Sartori, Luisa Gracio Ferreira, et al.
Publicado: (2023)

Pharmacological Effects and Potential Clinical Usefulness of Polyphenols in Benign Prostatic Hyperplasia
por: Mitsunari, Kensuke, et al.
Publicado: (2021)

Effect of oral intake of royal jelly on endothelium function in hemodialysis patients: study protocol for multicenter, double-blind, randomized control trial
por: Ohba, Kojiro, et al.
Publicado: (2021)

A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder
por: Kumar, Shailendra, et al.
Publicado: (2023)

Anticancer Effects of Green Tea and the Underlying Molecular Mechanisms in Bladder Cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2018)

A phase II dose-ranging study of mirabegron in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2013)

Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
por: Xu, Yankai, et al.
Publicado: (2017)

Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience
por: Allison, Sara J., et al.
Publicado: (2018)

Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)
por: Nakagomi, Hiroshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pnaepmh33v3d8e40dg4uhnggvv